The primary outcome was non-inferiority of IDeg 3TW compared with IGlar OD , as assessed by change in HbA ( 1c ) from baseline to 26 weeks ( non-inferiority limit of 0.4 % ) by ANOVA in an intent-to-treat analysis ( full analysis set ) .